Galapagos NV Stock Euronext Bruxelles
Equities
GLPG
BE0003818359
Biotechnology & Medical Research
Sales 2024 * | 337M 361M | Sales 2025 * | 314M 336M | Capitalization | 1.82B 1.94B |
---|---|---|---|---|---|
Net income 2024 * | -44M -47.09M | Net income 2025 * | -65M -69.56M | EV / Sales 2024 * | -4.8 x |
Net cash position 2024 * | 3.43B 3.68B | Net cash position 2025 * | 3.13B 3.35B | EV / Sales 2025 * | -4.17 x |
P/E ratio 2024 * |
-28.8
x | P/E ratio 2025 * |
-21.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.64% |
Latest transcript on Galapagos NV
Managers | Title | Age | Since |
---|---|---|---|
Paulus Stoffels
CEO | Chief Executive Officer | 62 | 22-03-31 |
Thad Huston
DFI | Director of Finance/CFO | 54 | 23-05-31 |
Investor Relations Contact | - | 20-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Dickinson
BRD | Director/Board Member | 54 | Mar. 26 |
Jérôme Contamine
BRD | Director/Board Member | 66 | 22-04-25 |
Simon Sturge
BRD | Director/Board Member | 65 | 23-09-18 |
1st Jan change | Capi. | |
---|---|---|
+3.13% | 42.11B | |
+48.83% | 40.08B | |
+8.49% | 40B | |
-10.82% | 26.87B | |
+8.26% | 24.58B | |
-23.69% | 18.44B | |
+1.58% | 11.94B | |
+32.83% | 11.66B | |
+6.63% | 11.01B |